231 related articles for article (PubMed ID: 2513898)
1. Aspirin use and chronic diseases: a cohort study of the elderly.
Paganini-Hill A; Chao A; Ross RK; Henderson BE
BMJ; 1989 Nov; 299(6710):1247-50. PubMed ID: 2513898
[TBL] [Abstract][Full Text] [Related]
2. Myocardial infarction and gastro-intestinal bleeding risks associated with aspirin use among elderly individuals with type 2 diabetes.
Sirois C; Moisan J; Poirier P; Grégoire JP
Ann Med; 2014 Aug; 46(5):335-40. PubMed ID: 24785356
[TBL] [Abstract][Full Text] [Related]
3. A prospective study of aspirin use and primary prevention of cardiovascular disease in women.
Manson JE; Stampfer MJ; Colditz GA; Willett WC; Rosner B; Speizer FE; Hennekens CH
JAMA; 1991 Jul 24-31; 266(4):521-7. PubMed ID: 2061978
[TBL] [Abstract][Full Text] [Related]
4. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women.
Ridker PM; Cook NR; Lee IM; Gordon D; Gaziano JM; Manson JE; Hennekens CH; Buring JE
N Engl J Med; 2005 Mar; 352(13):1293-304. PubMed ID: 15753114
[TBL] [Abstract][Full Text] [Related]
5. A long-term risk-benefit analysis of low-dose aspirin in primary prevention.
Wu IC; Hsieh HM; Yu FJ; Wu MC; Wu TS; Wu MT
Eur J Clin Invest; 2016 Feb; 46(2):130-40. PubMed ID: 26640116
[TBL] [Abstract][Full Text] [Related]
6. Epidemiological modelling of routine use of low dose aspirin for the primary prevention of coronary heart disease and stroke in those aged > or =70.
Nelson MR; Liew D; Bertram M; Vos T
BMJ; 2005 Jun; 330(7503):1306. PubMed ID: 15908442
[TBL] [Abstract][Full Text] [Related]
7. Antiplatelet agents in the prevention of cardiovascular morbidity and mortality in older patients with vascular disease.
Aronow WS
Drugs Aging; 1999 Aug; 15(2):91-101. PubMed ID: 10495069
[TBL] [Abstract][Full Text] [Related]
8. Sex differences in lifetime risk and first manifestation of cardiovascular disease: prospective population based cohort study.
Leening MJ; Ferket BS; Steyerberg EW; Kavousi M; Deckers JW; Nieboer D; Heeringa J; Portegies ML; Hofman A; Ikram MA; Hunink MG; Franco OH; Stricker BH; Witteman JC; Roos-Hesselink JW
BMJ; 2014 Nov; 349():g5992. PubMed ID: 25403476
[TBL] [Abstract][Full Text] [Related]
9. Stroke risk in older men and women: aspirin, estrogen, exercise, vitamins, and other factors.
Paganini-Hill A; Perez Barreto M
J Gend Specif Med; 2001; 4(2):18-28. PubMed ID: 11480094
[TBL] [Abstract][Full Text] [Related]
10. Proton-pump inhibitors reduce the risk of uncomplicated peptic ulcer in elderly either acute or chronic users of aspirin/non-steroidal anti-inflammatory drugs.
Pilotto A; Franceschi M; Leandro G; Paris F; Cascavilla L; Longo MG; Niro V; Andriulli A; Scarcelli C; Di Mario F
Aliment Pharmacol Ther; 2004 Nov; 20(10):1091-7. PubMed ID: 15569111
[TBL] [Abstract][Full Text] [Related]
11. Non-aspirin NSAIDs, cyclooxygenase-2 inhibitors and risk for cardiovascular events-stroke, acute myocardial infarction, and death from coronary heart disease.
Roumie CL; Choma NN; Kaltenbach L; Mitchel EF; Arbogast PG; Griffin MR
Pharmacoepidemiol Drug Saf; 2009 Nov; 18(11):1053-63. PubMed ID: 19637402
[TBL] [Abstract][Full Text] [Related]
12. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials.
Berger JS; Roncaglioni MC; Avanzini F; Pangrazzi I; Tognoni G; Brown DL
JAMA; 2006 Jan; 295(3):306-13. PubMed ID: 16418466
[TBL] [Abstract][Full Text] [Related]
13. Prophylactic aspirin and risk of peptic ulcer bleeding.
Weil J; Colin-Jones D; Langman M; Lawson D; Logan R; Murphy M; Rawlins M; Vessey M; Wainwright P
BMJ; 1995 Apr; 310(6983):827-30. PubMed ID: 7711618
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of Proton Pump Inhibitors in the Long-Term Aspirin Users: A Meta-Analysis of Randomized Controlled Trials.
Dahal K; Sharma SP; Kaur J; Anderson BJ; Singh G
Am J Ther; 2017; 24(5):e559-e569. PubMed ID: 28763306
[TBL] [Abstract][Full Text] [Related]
15. Aspirin use and incident stroke in the cardiovascular health study. CHS Collaborative Research Group.
Kronmal RA; Hart RG; Manolio TA; Talbert RL; Beauchamp NJ; Newman A
Stroke; 1998 May; 29(5):887-94. PubMed ID: 9596230
[TBL] [Abstract][Full Text] [Related]
16. Risks and benefits of COX-2 inhibitors vs non-selective NSAIDs: does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study.
Rahme E; Nedjar H
Rheumatology (Oxford); 2007 Mar; 46(3):435-8. PubMed ID: 17255138
[TBL] [Abstract][Full Text] [Related]
17. Discontinuation of low-dose aspirin therapy after peptic ulcer bleeding increases risk of death and acute cardiovascular events.
Derogar M; Sandblom G; Lundell L; Orsini N; Bottai M; Lu Y; Sadr-Azodi O
Clin Gastroenterol Hepatol; 2013 Jan; 11(1):38-42. PubMed ID: 22975385
[TBL] [Abstract][Full Text] [Related]
18. The natural history of prevalent ischaemic heart disease in middle-aged men.
Lampe FC; Whincup PH; Wannamethee SG; Shaper AG; Walker M; Ebrahim S
Eur Heart J; 2000 Jul; 21(13):1052-62. PubMed ID: 10843823
[TBL] [Abstract][Full Text] [Related]
19. A comparison of aspirin and clopidogrel with or without proton pump inhibitors for the secondary prevention of cardiovascular events in patients at high risk for gastrointestinal bleeding.
Hsiao FY; Tsai YW; Huang WF; Wen YW; Chen PF; Chang PY; Kuo KN
Clin Ther; 2009 Sep; 31(9):2038-47. PubMed ID: 19843493
[TBL] [Abstract][Full Text] [Related]
20. Update on aspirin in the treatment and prevention of cardiovascular disease.
Hennekens CH
Am J Manag Care; 2002 Dec; 8(22 Suppl):S691-700. PubMed ID: 12512736
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
